Insmed Inc (INSM) concluded trading on Wednesday at a closing price of $63.53, with 1.99 million shares of worth about $126.62 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 112.19% during that period and on Wednesday the price saw a loss of about -1.50%. Currently the company’s common shares owned by public are about 161.23M shares, out of which, 156.78M shares are available for trading.
Stock saw a price change of -7.90% in past 5 days and over the past one month there was a price change of 13.57%. Year-to-date (YTD), INSM shares are showing a performance of 105.00% which increased to 206.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $19.74 but also hit the highest price of $70.65 during that period. The average intraday trading volume for Insmed Inc shares is 3.46 million. The stock is currently trading -0.17% below its 20-day simple moving average (SMA20), while that difference is up 46.38% for SMA50 and it goes to 104.90% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insmed Inc (NASDAQ: INSM) currently have 161.23M outstanding shares and institutions hold larger chunk of about 92.35% of that.
The stock has a current market capitalization of $10.24B and its 3Y-monthly beta is at 1.16. It has posted earnings per share of -$5.24 in the same period. It has Quick Ratio of 1.61. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INSM, volatility over the week remained 4.53% while standing at 4.72% over the month.
Stock’s fiscal year EPS is expected to rise by 14.59% while it is estimated to increase by 14.03% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on April 23, 2024 offering a Buy rating for the stock and assigned a target price of $48 to it. Coverage by Wolfe Research stated Insmed Inc (INSM) stock as an Outperform in their note to investors on February 15, 2024, suggesting a price target of $42 for the stock. On December 08, 2023, Wells Fargo Initiated their recommendations, while on November 20, 2023, JP Morgan Resumed their ratings for the stock with a price target of $36. Stock get a Buy rating from Guggenheim on July 26, 2023.
